Recent News

• 07.23.2026 - Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
• 07.20.2026 - Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
• 06.05.2026 - Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 05.27.2026 - Collegium to Participate in 2026 Jefferies Global Healthcare Conference
• 05.12.2026 - Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
• 05.07.2026 - Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
• 04.23.2026 - Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
• 04.08.2026 - Collegium to Participate in Upcoming Investor Conferences
• 03.19.2026 - Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
• 03.05.2026 - Collegium to Present New Real-World Data at PainConnect 2026

Recent Filings

• 07.17.2026 - 144 Report of proposed sale of securities
• 07.15.2026 - 144 Report of proposed sale of securities
• 06.30.2026 - 8-K/A Current report
• 06.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.01.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 06.01.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 05.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities